OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	42
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	36
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	34
Indication-based pricing of the pharmaceuticals in Croatia: case-study	30
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	29
How to create value with constrained budgets in oncological care? A narrative review	21
The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations	17
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	17
Adherence to augmentation therapy for the treatment of major depressive disorder	17
Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective	16
Social care data in the UK; current landscape, challenges, and future recommendations	15
Cost-effectiveness of mechanical thrombectomy versus intravenous thrombolysis in acute ischemic stroke: a systematic review	13
Consumption of antidepressants and economic austerity in Brazil	11
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	11
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	10
The role of insurance policies in the drug pricing landscape	10
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	10
Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review	10
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	9
A methodological guide for implementing and interpreting results of probabilistic analysis	9
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	9
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study	9
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	9
The impact of under-investment on health in Southern and Central Eastern European Countries	9
The impact of bone turnover marker on medication adherence and the health economics-related consequences	9

Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	9
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	8
Digital measures in epilepsy in low-resourced environments	8
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	8
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis	8
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review	8
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis	8
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review	8
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	8
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis	8
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	8
Systematic reviews of machine learning in healthcare: a literature review	8
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	8
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture	8
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets	7
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation	7
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	7
How relevant is the BMI for cost-of-illness studies in the 21st century?	7
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve	7
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands	7
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	7
Economic evaluation of an add-on module to reduce intrusive suicidal mental images in patients with depressive symptoms	7
Systematic review on the use of cost-benefit analysis to evaluate food environment interventions	7
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments	7
Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination	7
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	7
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes	7
Management of low back pain in the Brazilian public health system: budget impact analysis of the implementation of Pilates exercises compared to usual care	7
Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries	6
Burden of disease of chronic pain in Ecuador	6
Bridging the gap: enhancing medication adherence through research and innovation	6
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions	6
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair	6
Valuing prevention: lessons and recommendations from a Dutch expert committee	6
The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data	6
Developing the Lebanese health economic evaluation guideline	6
Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework	6
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama	6
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders	6
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics	6
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation	6
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access	6
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change	6
Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies	6
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy	6
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	5
Economic benefits of global Collaborative Health technology	5
Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review	5
Workplace productivity losses due to cancer: findings from an Australian longitudinal population survey (2009–2021)	5
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	5

Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	5
The hidden burden of atopic dermatitis in central and Eastern European countries	5
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	5
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	5
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)	5
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	5
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	5
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	5
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
A comprehensive measurement of hemophilia economic burden in Iraq: a field-based study	4
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	4
The economics of prevention and quality of care: policy insights from the EU’s COVID-19 response	4
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	4
The economic impact of pharmacist intervention during pandemics	4
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece	4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning	4
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	4
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	4
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	4
Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands	4
Implementing a Managed Entry Agreement Framework in Cyprus	4
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	4
The value of functional genomics: a contingent valuation	4
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	4
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	4
The Lebanese health economic evaluation guideline	4
Cost-effectiveness of HIV prevention interventions in sub-Saharan Africa (2019–2025): a systematic review	4
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China	4
Correction	4
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system	4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	4
Digital decision aids and prenatal outcomes: a systematic review and meta-analysis	4
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	3
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model	3
Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves	3
Economics perspectives on understanding antimicrobial use and resistance: a scoping review from theory to practice	3
Integrated care in Western Europe: a wise solution for the future?	3
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	3
A review of caregiver costs included in cost-of-illness studies	3
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece	3
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China	3
Burden of disease of chronic pain in Colombia	3
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective	3
Perspectives in prospective comparative economic evaluations: a systematic review	3
Barriers to digital endpoints in data collection in low and middle-income countries	3
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	3
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	3
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	3
Normative data and socio-demographic determinants of the dermatology life quality index in a large online sample of the Hungarian population	3
Exploring the approach to parameter uncertainty in early economic evaluations of surgical technology – a systematic review	3
Pharmacovigilance and outcomes: experience from Saudi Arabia narrative review	3
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia	3
Public value judgments about the criteria for reimbursement of medicines in South Korea	3
A pre-vaccine analysis using the Health Belief Model to explain parents’ willingness to vaccinate (WTV) their children in the United States: implications for vaccination programs	3
Cost-utility analysis of Lenvatinib vs. Sorafenib in unresectable hepatocellular carcinoma in Iran	3
Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024	3
What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system	3
Budget impact of low-dose computed tomography screening for lung cancer in Argentina	3
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	3
How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021	3
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program	3
Negating the burden of hip fracture in high-risk populations: a narrative review of epidemiology, costs, and multifaceted mitigation strategies	3
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	3
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	3
How can patients shape digital medicine? A rapid review of patient and public involvement and engagement in the development of digital health technologies for neurological conditions	3
Willingness to pay for a quality-adjusted life year (QALY) in Pakistan: implications for health policy	3
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention	3
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model	3
Financial evaluation of value-creating biosimilar development candidates: a business case study of low-, medium- and high-sales biosimilars	3
The health production model and the crucial role of health promotion	3
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare	3
Cost-effectiveness of MRI strategies for early prostate cancer detection: a systematic review	3
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	3
The short-term impact of copayment reductions for government subsidised medicines in Australia	3